

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Rebecca Anderson
Group Art Unit: 1626
Applicant: Michael Hale, et al.
Serial No.: Not Yet Assigned
Filing Date: Herewith
For: ISOXAZOLE COMPOSITIONS USEFUL AS
INHIBITORS OF ERK

Cambridge, Massachusetts
July 24, 2003

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:


Transmitted herewith is an Information Disclosure Statement in the
above-identified application. This Statement is submitted:

- ☒ within three months of the application filing date;
- ☐ more than three months from the application filing date but
before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement
requires no fee. However, if for any reason a fee is due, the Commissioner is hereby
authorized to charge payment of any fees required in connection with this Information

Disclosure Statement to Deposit Account No. 50-0725. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



Andrea L. C. Robidoux, Registration No. 47,902
Agent for Applicants
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Tel.: (617)444-6731
Fax.: (617)444-6438

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Rebecca Anderson
Group Art Unit: 1626
Applicant: Michael Hale, et al.
Serial No.: 09/953,120
Filing Date: September 14, 2001
For: ISOXAZOLE COMPOSITIONS USEFUL AS
INHIBITORS OF ERK

Cambridge, Massachusetts
July 24, 2003

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their agent, make of record the documents listed on the completed Form PTO-1449, submitted herewith in duplicate.

This Statement is being submitted concurrently with the application filing and before the mailing of a first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 50-0725.


A copy of each of the documents listed above are not provided because they were previously submitted to the Patent Office in prior application number 09/953,120

filed September 14, 2001 and relied upon for an earlier filing date under 35 U.S.C. § 120.

Applicants request that these documents: (1) be fully considered by the Examiner during examination of this application, and (2) be printed on any patent that may issue from this application. A duplicate copy of the PTO-1449 form is enclosed herewith.

Applicants request that the Examiner return to applicants with the next communication a copy of the enclosed PTO-1449 form duly initialed.

Respectfully submitted,



Andréa L. C. Robidoux, Registration No. 47,902
Agent for Applicants
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Tel.: (617)444-6731
Fax.: (917)444-6438

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned
	Filing Date	Herewith
	First Named Inventor	Hale, et al.
	Group Art Unit	1626
	Examiner Name	Rebecca Anderson
	Attorney Docket Number	VPI/00-122 DIV2 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,470,862	11/28/95	Lin, et al	514	341	
	A2*	5,498,720	3/12/96	Lee	546	276	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1*	DE	44 38 824	Schering AG	April 20, 1995		X
	B2*	WO	98/15542	Lundbeck	April 16, 1998		
	B3*	WO	98/35944	Bayer	August 20, 1998		
	B4*	WO	01/57022	Vertex	August 9, 2001		
	B5*	WO	01/56557	Vertex	August 9, 2001		
	B6*	WO	99/61440	Smithkline Beecham	December 2, 1999		
	B7*	JP	0827130	Teikoku	January 30, 1996		X
	B8*	JP	2000 086657	Teikoku	March 28, 2000		X

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Holland et al, "Heterocyclic tetrazoles, a new class of lipolysis inhibitors", J. Med. Chem., 10(2): 149-154, 1967
	C2*	Almerico et al, "Polycondensed nitrogen heterocycles. Part 17. Isoxazolo-4,3-pyrazolo-3,4-f-1,2,3-triazepine. A new ring system", J. Heterocyclic Chem., 24(5): 1309-1311, 1987
	C3*	Tanaka et al, "Synthesis and properties of H-1,2,3-triazoles", Tetrahedron, 29(21): 3271-3285, 1973
	C4*	Bang et al, "Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships", J. Med. Chem., 40(18): 2831-2842, 1997
	C5*	Jones et al, "1,3-Dipolar addition reactions with vinylpyrroles", Heterocycles, 14(2): 185-188, 1980
	C6*	Ajello et al, "New syntheses of condensed heterocycles from isoxazole derivatives. III. s-Triazolof[3,4]pyridazines", J. Het. Chem., 9(4): 1169-1170, 1972

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C7*	Aiello et al, "Synthesis and antimicrobial activity of new 3-(1R-3(5)-methyl-4-nitroso-1H-5(3)-pyrazolyl)-5-methylisoxazoles", Bioorg. Med. Chem., 8(12): 2719-2728, 2000
	C8*	Musante et al, Gazz. Chim. Ital., 79, 1949

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/953,120, filed September 14, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned
	Filing Date	Herewith
	First Named Inventor	Hale, et al.
	Group Art Unit	1626
	Examiner Name	Rebecca Anderson
	Attorney Docket Number	VPI/00-122 DIV2 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,470,862	11/28/95	Lin, et al	514	341	
	A2*	5,498,720	3/12/96	Lee	546	276	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1*	DE	44 38 824	Schering AG	April 20, 1995		X
	B2*	WO	98/15542	Lundbeck	April 16, 1998		
	B3*	WO	98/35944	Bayer	August 20, 1998		
	B4*	WO	01/57022	Vertex	August 9, 2001		
	B5*	WO	01/56557	Vertex	August 9, 2001		
	B6*	WO	99/61440	Smithkline Beecham	December 2, 1999		
	B7*	JP	0827130	Teikoku	January 30, 1996		X
	B8*	JP	2000 086657	Teikoku	March 28, 2000		X

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Holland et al, "Heterocyclic tetrazoles, a new class of lipolysis inhibitors", J. Med. Chem., 10(2): 149-154, 1967
	C2*	Almerico et al, "Polycondensed nitrogen heterocycles. Part 17. Isoxazolo-4,3-pyrazolo-3,4-f-1,2,3-triazepine. A new ring system", J. Heterocyclic Chem., 24(5): 1309-1311, 1987
	C3*	Tanaka et al, "Synthesis and properties of H-1,2,3-triazoles", Tetrahedron, 29(21): 3271-3285, 1973
	C4*	Bang et al, "Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships", J. Med. Chem., 40(18): 2831-2842, 1997
	C5*	Jones et al, "1,3-Dipolar addition reactions with vinylpyrroles", Heterocycles, 14(2): 185-188, 1980
	C6*	Ajello et al, "New syntheses of condensed heterocycles from isoxazole derivatives. III. s-Triazolo[3,4]pyridazines", J. Het. Chem., 9(4): 1169-1170, 1972

OTHER NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C7*	Aiello et al, "Synthesis and antimicrobial activity of new 3-(1R-3(5)-methyl-4-nitroso-1H-5(3)-pyrazolyl)-5-methylisoxazoles", Bioorg. Med. Chem., 8(12): 2719-2728, 2000
	C8*	Musante et al, Gazz. Chim. Ital., 79, 1949

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/953,120, filed September 14, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.